Most people experience several episodes of acute infectious disease each year. Despite the diverse organisms that cause these illnesses and the different body tissues that they infect (for example, upper respiratory, urinary or gastrointestinal systems), a similar set of constitutional symptoms typically occurs. These include fever, achiness, loss of appetite and sleepiness, so that most people want to crawl into bed, pull the covers over their heads and go to sleep. Known as the sickness syndrome, these autonomic, endocrine and behavioral changes are an adaptive CNS response to help fight infectious diseases [1] [2] [3] [4] . Fever (elevation of body temperature) helps the immune system fight infections by increasing activity of white blood cells and inhibiting growth of many microorganisms 1,5 ; achiness, fatigue and sleepiness conserve energy that is needed to fight the infection and elevate body temperature; and loss of appetite minimizes blood glucose 6 , which is a preferred fuel for many microorganisms.
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Over the last 2 decades, it has become clear that the sickness syndrome is mediated by the brain response to inflammatory molecules produced during infection and other inflammatory diseases (such as arthritis, autoimmune disorders and some types of cancer) (see Box 1). Researchers have found that prostaglandins link systemic inflammation to brain response by their ability to signal across the blood-brain barrier (BBB). The availability of molecular tools and mouse models for manipulating prostaglandin synthetic enzymes and receptors has allowed investigators to begin mapping the brain circuitries that are engaged by prostaglandins to cause the sickness syndrome. In this Review, we will first provide an overview of how immune mediators affect the brain and then examine in detail the circuitry mediating each aspect of the sickness syndrome.
Prostaglandins mediate many aspects of the sickness syndrome During an infection, several signals activate immune response. First, many immune system cells bear receptors for common macromolecules present on invading organisms. For example, CD14 is a protein that binds lipopolysaccharide (LPS), a common constituent of bacterial cell walls, and activates Toll-like receptor 4, which triggers an intracellular cascade of events activating immune responses 7 . In this innate immune response, the activated cells release an array of hormones called cytokines, such as interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α. Some cytokines attract other immune cells to the site of the inflammation, whereas others act on a variety of other peripheral tissues to release further chemical mediators of inflammation.
Among these mediators are the prostaglandins. Prostaglandins are derivatives of arachidonic acid, which is converted to prostaglandin H 2 by cyclooxygenase (COX). There are two forms of COX: COX1 is constitutively active in many tissues, and COX2 is mainly induced during inflammatory responses 8 . COX2 is expressed constitutively by some neurons in the brain, but systemic LPS induces COX2 in the brain only in perivascular and endothelial cells along small venules, and IL-1β activates COX2 primarily in perivascular cells [9] [10] [11] . These venules are found throughout the brain but are densest in the preoptic area, the base of the hypothalamus, and the ventrolateral medulla and nucleus of the solitary tract. Several more enzymes then convert prostaglandin H 2 to other prostaglandins, to prostacyclins or to leukotrienes. For the purpose of this Review, we will concentrate on two of these molecules, prostaglandin E 2 (PGE 2 , produced by microsomal PGE synthase 1, or mPGES1) and prostaglandin D 2 (PGD 2 , produced by lipocalin PGD synthase, or L-PGDS), as, for reasons reviewed below, these molecules appear to be most relevant for producing the sickness syndrome. PGE 2 acts on four different EP receptors, EP1-EP4, which are expressed in different parts of the central nervous system 12 . PGD 2 acts on the DP1 receptor, which is mainly found in the meninges along the surface of the brain, especially in the area ventral to the hypothalamus. A DP2 receptor has recently been described, but it is present at only very low levels in the brain, and as yet no functions have been attributed to it in that site.
For many years, researchers have debated whether the sickness syndrome is due to the action of cytokines directly on the brain or through an intermediary such as prostaglandins (see Box 2). Inflammatory cytokines such as IL-1β, IL-6 and TNF-α, which can cause fever responses (and are therefore sometimes called endogenous pyrogens) and other aspects of the sickness syndrome, are too bulky to cross the BBB in large amounts directly 13, 14 . Thus, although they can cause local inflammation if injected directly into the brain, these responses are more akin to encephalitis, whereas in this Review we will concentrate on CNS responses caused by systemic immune activation.
Cytokines can, however, enter the brain in small quantities at the circumventricular organs, small islands of neural tissue along the surface of the cerebral ventricles that lack a BBB, allowing circulating proteins to interact with nearby neurons 13 . In addition, there is evidence that the inflammatory cytokines can be actively transported into the CNS 14 , but the physiological significance of this process is not clear. The strongest argument that cytokines require prostaglandin intermediates to activate many of the components of the sickness syndrome is one that is exploited by millions of people on a daily basis: COX inhibitors such as aspirin, ibuprofen or naproxen can substantially reduce fever, sleepiness, pain and anorexia. The neural circuits underlying these prostaglandin-dependent components of the sickness syndrome have been intensively studied and will be the focus of the remainder of this Review.
Fever
Fever is a brain-regulated elevation of body temperature that occurs during an inflammatory response. After peripheral administration of LPS, fever occurs in several phases, each representing a distinct burst of activity of thermoregulatory effectors and a distinct rise in body temperature 15 . Fever responses are blocked by systemic administration of COX inhibitors and are absent in mice in which the Ptges gene, encoding mPGES1, has been deleted 16 , indicating that these responses are mediated by PGE 2 . However, the PGE 2 that mediates different phases of fever may come from different sources. The first (early) phase of LPS fever is triggered by PGE 2 of peripheral origin, as neutralization of circulating PGE 2 by a PGE 2 antibody that does not cross the BBB blocks this response 17 . LPS acts on Toll-like receptor 4 on hepatic (Kupffer cell) and pulmonary macrophages, in which there is upregulation of mRNA and protein for phospholipase A2 (which produces arachidonic acid), COX2 and mPGES1, which in turn results in an increase in PGE 2 in both venous and arterial blood 17, 18 . The PGE 2 binds to albumin, which transports it and may protect it from enzymatic inactivation 18 . PGE 2 may dissociate from albumin and then be carried across the BBB to its site of action by specialized transporters that are expressed in the hypothalamus 18 .
The more prominent later phases of fever, which start at about 1 hour after LPS administration and last for several hours 15 , are mediated by PGE 2 produced by COX2 in perivascular and endothelial cells 2, 9, 10, 19 . IL-1β and low doses of LPS upregulate COX2 expression in perivascular cells, whereas higher doses of LPS also increase COX2 in endothelial cells, mainly along venules 9, 11 . However, only endothelial cells have been found to produce mPGES1 in adult brain 20 , so they are the source of PGE 2 in the later phases of fever. Induction of COX2 and mPGES1 in brain coincides with the later febrile phases 18, 21 . Although studies in knockout mice have demonstrated the indispensable roles of COX2 (ref. 22 ) and mPGES1 (ref. 16) in LPS-induced fever, cell type-specific modulation of expression of these enzymes will still be needed to determine the cellular source
Box 1 Models of inflammation
In this review, we emphasize the sickness syndrome, a remarkably common pattern of CNS response to inflammation from a variety of different causes, which includes fever, sleepiness, anorexia, hyperalgesia and corticosteroid release. However, infections can occur in any organ of the body, and each part of the body is differentially susceptible to specific pathogens. These may be bacteria, viruses or fungal infections, and each species and strain of pathogen activates the immune system differently. Similarly, in experimental models of inflammation, specific details of the sickness syndrome vary depending on the species of host animal that is studied, the route of administration (intramuscular, intraperitoneal, intravenous, intracerebral), the response that is measured and the timing of the measurement, and the nature of the inflammatory stimulus (for example, responses to bacterial molecules such as LPS may differ among strains of bacteria, and responses to some products not discussed here, such as Staphylococcus enterotoxin B, may be very different from the response to LPS). Because these infectious stimuli set off a cascade of hormones, called cytokines, that are made by white blood cells and other tissues, some models use injections of specific cytokines, such as IL-1β or TNF-α, to initiate the response. Even such factors as the strain of rat or mouse that is used, the time of day of administration and the time point at which the response is measured can affect the outcome.
In this review, we focus on the acute (1-4 hours) response to intravenous or intraperitoneal challenge with LPS during the daytime, to examine the brain response to a generalized systemic inflammatory event in the absence of an infection. We further concentrate on mouse and rat models, as the most studies about neural circuitry engaged by inflammation have been done in these species. Finally, we limit our review to the effects that are mediated by prostaglandins, which predominate in many of the components of the sickness syndrome. Because the prostaglandin synthetic enzymes and receptors are known, have been mapped in the brain, and in most cases have been targeted with knockout models and specific drugs, the effects of the prostaglandin-mediated responses on specific brain circuits have been studied in the greatest detail. However, it is likely that we will identify more CNS circuitry mediating the effects of inflammation as other models and non-prostaglandin-dependent responses come under more intense investigation in the future.
Box 2 The vagus nerve in immune signaling
The role of the vagus nerve in signaling the presence of peripheral inflammatory mediators has been controversial. As we have reviewed elsewhere (for references, see ref. 96) , there was a burst of enthusiasm for the vagal theory in the early 1990s based on studies by several labs demonstrating that subdiaphragmatic vagotomy prevents fever responses to i.p. LPS or IL-1β. However, it soon became apparent that surgical vagotomy causes gastric stasis, slow bowel transit and poor absorption of nutrients, resulting in malnutrition and inability to mount a thermogenic response 97 . Most studies of the effects of vagotomy in rats that were done after 1997 involved placing animals on a liquid diet to prevent malnutrition and associated disorders. In these later studies, surgical vagotomy was found to have little effect on the febrile response to LPS or IL-1β [98] [99] [100] , except after very low doses of pyrogens (for example, 500-2,000 ng kg -1 for i.v. LPS and 100-500 ng kg -1 for i.v. IL-1β in rats). Similarly, subdiaphragmatic vagotomy followed by liquid diet in mice and rats has been reported to have minimal effects on anorexia induced by i.p. LPS or IL-1β, on open-field investigation after IL-1β or on corticosteroid secretion after IL-1β or LPS 64, 80 . Hence, although vagal circuitry certainly is activated by systemic LPS or IL-1β 70 , the contribution of vagal signaling to the sickness syndrome is not entirely clear and is not discussed in this review.
npg r e v i e w of pyrogenic PGE 2 (ref. 18 ). The interplay of PGE 2 -degrading and transporting systems may also regulate brain PGE 2 during fever 18 . PGE 2 acts on neuronal receptors of the EP family in the thermoregulation circuitry to trigger fever (Fig. 1) . The EP3 receptor is now viewed as the principal type responsible for fever [23] [24] [25] , but EP1 receptors may also contribute under some conditions 25 . The EP3 receptor occurs in several isoforms, and in rodents isoforms α and γ are strongly expressed in the median preoptic nucleus (MnPO) [24] [25] [26] and are thought to mediate fever 27 . The MnPO is also the most responsive part of the brain to both the pyrogenic action of PGE 2 (ref. 28 ) and the antipyretic action of intracerebral injection of ketorolac, a COX inhibitor, after LPS administration 29 . Focal elimination of EP3 receptors in the MnPO has shown that their presence is required for fever following systemic LPS or intracerebroventricular (i.c.v.) PGE 2 (ref. 24) . Preoptic EP3-expressing neurons produce GABA 30 and are thought to inhibit downstream neurons that drive increases in body temperature. Typically, α and γ EP3 receptors inhibit neuronal function through G i protein-mediated inhibition of adenylate cyclase. Hence, it is likely that PGE 2 binding to EP3 receptors reduces the activity of MnPO neurons, resulting in disinhibition of downstream targets that elevate body temperature 31 .
What targets do EP3-expressing preoptic neurons engage to increase body temperature during fever? The autonomic contribution to fever after systemic LPS 32 or i.c.v. PGE 33 relies primarily on two responses: cutaneous vasoconstriction (particularly of the tail skin, the principal means by which rodents elevate body temperature in a warm environment) and activation of thermogenesis in brown adipose tissue (which rodents recruit to elevate body temperature in a cool environment). These responses are controlled by two populations of GABAergic preoptic neurons that are warm sensitive (that is, fire faster when warmed). One population, located mainly in the MnPO, regulates tail skin vasoconstriction by means of projections to the rostral medullary raphe (RMR), which in turn directly innervates sympathetic preganglionic neurons. These EP3-expressing MnPO neurons are probably also involved in baseline thermoregulation 34 . The other group is located more caudally and laterally in the dorsolateral preoptic area and regulates brown adipose tissue thermogenesis through projections to the dorsomedial hypothalamus (DMH), which also projects to the RMR 35, 36 . Hence, in rodents, PGE 2 triggers autonomic heat conservation and heat production by acting on EP3 receptors to reduce activity of preoptic GABAergic neurons, thus disinhibiting sympathetic activation of tail skin vasoconstriction and brown adipose tissue thermogenesis.
The fever response to LPS is opposed by central pathways involving α-melanocyte stimulating hormone (α-MSH) acting on melanocortin (MC) 3 and 4 receptors 37 . The MC3 and MC4 blocker SHU-9119 increases fever due to intraperitoneal (i.p.) LPS but blocks anorexia (see below), suggesting that there is tonic action of α-MSH on MC3 and MC4 receptors that opposes hyperthermia but mediates anorexia. As the DMH neurons that project to the RMR have high levels of MC4 receptors 38 , which are inhibitory, this is a likely site where α-MSH might inhibit fever. LPS fever also involves several thermoregulatory behaviors, including selection of a higher ambient temperature, or warmth seeking 39 . Neural pathways controlling thermoregulatory behaviors differ from those controlling autonomic thermoeffectors 31, 36, 40 . They do not travel through the preoptic area but instead may follow thalamo-cortical pathways for discriminatory thermal sensitivity 41 . Rats with large electrolytic lesions of the preoptic area still exhibit excellent behavioral thermoregulation, including the ability to generate fever after LPS administration by moving to a higher ambient temperature, even though the same rats are incapable of mounting autonomic thermoregulatory responses 39 . The locus of PGE 2 action for behavioral thermoregulation remains unknown.
Sleepiness
Irresistible, prolonged sleep is a major aspect of the sickness syndrome. Normally, about 25% of the sleep period in humans is spent in rapid eye movement (REM) sleep, a state characterized by dreaming, fast cortical activity and muscle paralysis, and the remaining 75% is spent in non-REM (NREM) sleep, a state of slow cortical activity and low metabolism. Wakefulness is driven by monoaminergic and cholinergic neurons that activate the forebrain, but during sleep these wake-promoting systems are inhibited by GABAergic neurons in the ventrolateral preoptic nucleus (VLPO) and adjacent parts of the preoptic area 42 (Fig. 2) . This action of the VLPO is necessary to produce adequate amounts of sleep, and a key target of the VLPO is the histaminergic tuberomammillary nucleus (TMN), which is a principal wake-promoting site. Researchers are now beginning to understand how inflammatory mediators act through these pathways to alter sleep.
In healthy human subjects, as in rats and mice, low to moderate doses of intravenous LPS increase deep NREM sleep and reduce REM sleep [43] [44] [45] . Some components of the sleep response to systemic inflammation may be mediated by direct effects of cytokines on neurons or through the effects of other mediators such as nitric oxide on the brain 46, 47 . However, the importance of prostaglandins as mediators of the sleep response is demonstrated by the fact that even after i.c.v. administration of TNF-α, i.c.v. injection of a COX2 inhibitor blocks the increase in NREM sleep 48, 49 .
Hayaishi, Urade and colleagues have identified PGD 2 as a major sleep-promoting factor. Incubation of preoptic brain slices with LPS induces production of PGD 2 (ref. 50) , and infusion of PGD 2 in the subarachnoid space just ventral to the VLPO produces large and sustained increases in NREM sleep 51 . PGD 2 is likely to originate in the meninges, as the synthetic enzyme L-PGDS is found in the meninges and choroid plexus but not in the brain parenchyma 52 . PGD 2 then activates target cells through DP1 receptors, which are most abundant in the meninges just ventral to the VLPO 53 . DP1 signaling in turn induces release of adenosine, which acts as a paracrine signaling Figure 1 Neuronal pathways causing fever during systemic inflammation in response to PGE 2 . PGE 2 is produced by endothelial and perivascular cells along small venules at the edges of the brain, particularly in the preoptic area. It acts on EP3 receptors (EP3R) to inhibit neurons in the median preoptic nucleus (MnPO). Many of these neurons are GABAergic, and their activity inhibits neurons in the dorsomedial nucleus of the hypothalamus (DMH) and rostral medullary raphe (RMR) that act to increase body temperature. RMR neurons use glutamate and serotonin (5-HT) to excite sympathetic preganglionic neurons in the intermediolateral column of the spinal cord (IML), which activate brown adipose tissue (to produce heat) and cutaneous vasoconstriction (particularly in the tail artery, to conserve heat). Thus, PGE 2 in the MnPO disinhibits these heatproducing and heat-conserving pathways and elevates body temperature. Blue arrows, excitation; red, inhibition. 54 . Adenosine may act in part by inhibiting wake-active neurons through A1 receptors [55] [56] [57] , but excitatory adenosine A2a receptors also contribute. Infusion of an adenosine A2a agonist in the subarachnoid space just ventral to the preoptic area promotes sleep, and the sleep-promoting response to PGD 2 can be reduced by an A2a antagonist 58, 59 . It remains unclear how adenosine activates VLPO neurons, which show fewer inhibitory synaptic inputs but no direct response to adenosine 56 , but this question can now be addressed by focally expressing or deleting the A2a receptor gene. For example, elimination of the A2a receptor in the nucleus accumbens was recently shown to block the wake-promoting effects of caffeine, which is an adenosine antagonist 60 . These observations suggest that A2a receptors in the nucleus accumbens shell promote sleep, but it has not been explored whether this signaling pathway mediates the increase in NREM sleep with systemic inflammation.
Whereas PGD 2 ultimately activates sleep-promoting neurons in the VLPO, PGE 2 activates histaminergic, wake-promoting TMN neurons. Infusion of PGE 2 in the TMN markedly increases wakefulness 61 . In addition, TMN neurons express EP4 receptors, and infusion of an EP4 agonist in this region increases histamine release and wakefulness 62 . Although this effect may seem to run counter to the sleep-promoting effects of PGD 2 , sleep becomes more fragmented in people treated with relatively high doses of LPS 43 . Hence with mild to moderate levels of inflammation, PGD 2 may activate the VLPO sufficiently to suppress activity in the TMN and increase sleep, whereas with more severe inflammation, PGE 2 may activate TMN neurons sufficiently to overcome VLPO inhibition and produce fragmented, fitful sleep or even an agitated delirium.
Anorexia
In the 24 hours after a single dose of i.p. LPS, both rats and mice eat and drink less and lose weight [63] [64] [65] . The anorexia and weight loss are eliminated by systemic administration of a COX inhibitor (for example, indomethacin) before the LPS, so these responses are likely to be mediated predominantly if not exclusively by prostaglandins. A relatively small, early component of the anorexia appears to be sensitive to COX1 inhibitors and is lost in COX1-null (Ptgs1 -/-) mice, whereas the later and larger component is sensitive to COX2 inhibitors 63 . Like LPS, IL-1β administered i.p. produces anorexia that is attenuated in COX2-null (Ptgs2 -/-) mice 63 . Thus, the bulk of the response (the response after the first hour) is likely to be due to COX2-mediated production of prostaglandins.
The anorexic response can be replicated by i.c.v. injection of PGE 2 , and the response to i.p. IL-1β administration is eliminated in mice that lack mPGES1 (ref. 66) , suggesting involvement of PGE 2 . The anorexic effect of PGE 2 i.c.v. can be reversed with the EP4 receptor antagonist ONO-AE3-208, whereas i.c.v. administration of the EP4 agonist ONO-AE1-329 mimics the effect of PGE 2 on feeding 67 . Because the EP4 receptor is present at high levels in the paraventricular nucleus of the hypothalamus (PVH) and its expression is increased by intravenous (i.v.) LPS 68 , some of the CNS effects of PGE 2 may be mediated by the PVH (Fig. 3) . Because i.c.v. PGD 2 causes an increase in feeding in mice 69 , it is unlikely to contribute to the anorexia seen after systemic LPS (except perhaps to limit it).
After i.v. LPS, there is activation of expression of cFos, an earlyresponse protein that is used as a marker of neuronal activity, in neurons in the PVH, as well as in the arcuate nucleus, the DMH and the lateral hypothalamic area 70 . In the PVH, many of the cFos + neurons are immunoreactive for corticotropin-releasing hormone (CRH), whereas in the arcuate nucleus many of the cFos + neurons stain with antibodies to pro-opiomelanocortin (POMC) peptides 71 . The POMC neurons are thought to inhibit feeding during the first few hours after LPS, whereas the CRH neurons are thought to mediate an increase in corticosteroid production (see below) that may increase feeding at later times.
Recent studies have emphasized the presence of two populations of neurons in the arcuate nucleus with opposite effects on feeding. Figure 3 Neuronal pathways that may cause anorexia during systemic inflammation, in response to PGE 2 . PGE 2 produced by vascular and perivascular cells in the region of the median eminence acts via EP4 receptors to activate pro-opiomelanocortin (POMC) expressing neurons in the arcuate nucleus. These neurons produce α-melanocyte stimulating hormone (α-MSH), which acts through melanocortin 4 (MC4) receptors to inhibit neurons in the DMH, paraventricular nucleus (PVH) and lateral hypothalamic area (LHA) that otherwise promote feeding, by means of descending projections to autonomic regions (IML, intermediolateral column of the spinal cord; DVC, dorsal vagal complex) that control the gastrointestinal (GI) system and by ascending orexin (ORX)-containing projections to the cerebral cortex. During systemic inflammation there is also a prostaglandinmediated fall in serum ghrelin, a peptide made in the stomach that crosses the blood-brain barrier in the median eminence to promote feeding by acting on neurons in the DMH and PVH, as well as on arcuate neurons containing agouti-related peptide (AgRP). GI autonomic feeding cues Figure 2 Neuronal pathways promoting sleep during systemic inflammation, in response to PGD 2 . During systemic inflammation, PGD 2 is made by leptomeningeal cells; it acts on cells in the leptomeninges that have DP1 receptors and produce adenosine in response. Adenosine acts on A2a receptors (A2aR) in the forebrain to activate the nucleus accumbens (NAc) and the ventrolateral preoptic nucleus (VLPO). The VLPO neurons directly inhibit the arousal system, including the histaminergic tuberomammillary nucleus (TMN), the serotoninergic dorsal raphe nucleus (DR) and the noradrenergic locus coeruleus (LC), thus promoting sleep. The mechanism by which NAc causes sleepiness is not yet established, but this nucleus has extensive GABAergic projections to the perifornical region containing neurons that express the neurotransmitter orexin, which promotes wakefulness. PGE 2 produced during inflammation may have a counteracting effect, by exciting TMN neurons via EP4 receptors, perhaps explaining why the excess sleep observed during inflammation tends to be fragmented by more frequent awakenings. The POMC neurons express cFos after administration of leptin, a hormone that signifies adequate availability of energy substrates 72 . They project to the PVH, the DMH and the lateral hypothalamic area, where they act on MC4 receptors that inhibit feeding. Other arcuate neurons, which produce neuropeptide Y and agouti-related protein (AgRP), project to the same targets 73 , where AgRP acts as an endogenous antagonist of the MC4 receptor 74 . The arcuate neuropeptide Y/AgRP neurons, which are activated by high levels of the appetite-promoting hormone ghrelin, help drive feeding 75 . They also contain GABA, with which they directly inhibit the POMC neurons and other brainstem feeding circuitry 76 . This network of structures is thought to modulate feeding, as well as energy expenditure and body weight, through a variety of CNS projections to autonomic, endocrine and behavioral targets. Thus the activation of neurons in these structures after i.v. LPS likely reflects their roles in regulating feeding. For example, the blockade of MC3 and MC4 receptors by SHU-9119 is known to prevent the anorexia after i.p. LPS 37 , indicating that the POMC/α-MSH projections may be key for the response. It will be important to explore the roles of the targets of this pathway that express MC3 and MC4 receptors and to identify other chemically defined populations of neurons to determine which of them contribute to the anorexia.
However, i.p. LPS also causes a fall in levels of ghrelin, a peptide secreted by gastric cells that increases feeding 77 . Replacing the ghrelin restores feeding after i.p. LPS. The effect of LPS on ghrelin release is blocked by i.p. indomethacin 77 , so it is prostaglandin-dependent, but whether the prostaglandins that suppress ghrelin secretion act on the brain or periphery has not been studied. Hence it is possible that the anorexia associated with i.p. LPS administration may be mediated by PGE 2 acting at several different levels in the system that regulates feeding and energy metabolism.
Hyperalgesia
Like anorexia, the influence of inflammation on pain perception may also be mediated at different levels of the neuraxis. The classic signs of inflammation, tumor, calor, rubor and dolor (swelling, warmth, redness and pain), are due to the local effects of inflammatory mediators, which cause vasodilation and edema and can sensitize the terminals of nociceptive neurons, causing local pain. However, the central response to pain is also susceptible to modulation at several levels, from the spinal cord to the brainstem and the forebrain. The tests used to measure pain responses are dependent on different levels of the neuraxis and therefore can produce different results, even in the same model of inflammation. In addition, the effects of inflammation on pain are dynamic, showing hyperalgesia initially but, in some assays, a later analgesic effect 4 . The later analgesia may be due to cascades of additional mediators, such as corticosteroids, and so we will focus here on the initial, hyperalgesic response to acute inflammation.
Some aspects of the hyperalgesic response to inflammation apparently are not mediated by prostaglandins. For example, after i.p. injection of LPS, there is a reduction in the latency of the tail-flick response, a pain assay that measures tail movement in response to local heating and is generally agreed to be spinally mediated. This response is unaffected by systemic administration of the COX inhibitor indomethacin 78 . This is understandable, as i.p. LPS causes expression of inflammatory mediators that can irritate local peripheral nerves. Thus COX inhibitors may be unable to eliminate the local pain and the effects on the associated spinal reflexes. By contrast, the latency to paw withdrawal from noxious heat, which is sensitive to supraspinal influences, is also reduced after i.p. LPS, but it is restored to near normal levels by systemic administration of drugs that inhibit prostaglandin synthesis 79 .
The i.v. LPS model is better for examining the effect of inflammation on overall CNS response to pain, as there is no local site of inflammation and LPS enters the circulation immediately, rather than by gradual hematogenous and lymphatic uptake 80 . In this model, initial hyperalgesia is followed in a few hours by hypoalgesia 4, 81 . After i.v. LPS even at relatively low doses (for example, 10-100 µg per kilogram body weight), there is initially a reduction in the latency to paw withdrawal to noxious heat 82 . This hyperalgesic response is abolished by injecting a nonselective COX inhibitor (diclofenac) or a COX2 selective inhibitor (NS-398) into the preoptic area (but not into other parts of the hypothalamus). The medial preoptic region of the hypothalamus has extensive projections to the midbrain periaqueductal gray matter 83, 84 , which is known to mediate antinociceptive responses (Fig. 4) .
There is some evidence that LPS-induced hyperalgesia may be reduced in animals lacking EP3 (but not EP1, EP2 or EP4) receptors 85 , but whether this effect is central or peripheral has not been examined. However, after i.c.v. injection of PGE 2 , there is also a reduction in latency to paw withdrawal and an increase in the firing rate of spinal trigeminal neurons to noxious toe pinching 81 . This hyperalgesic effect is replicated by i.c.v. injection of an EP3 agonist (M&B28767) but not an EP1 agonist (17-phenyl-ω-trinor-PGE 2 ) or EP2 agonist (butaprost), and the most sensitive site at which either PGE 2 or the EP3 agonists cause hyperalgesia is the preoptic area. Given that EP3 receptors in the preoptic area are highly concentrated in the MnPO 24, 68 , which, along with the adjacent medial preoptic nucleus, projects extensively to the periaqueductal gray matter 83 , this site is a likely locus through which PGE 2 may produce not only fever but also hyperalgesia. However, this hypothesis remains to be tested.
Elevated corticosteroids
Corticosteroid secretion is elevated by a variety of stressful stimuli, including acute inflammation. However, the degree to which this response depends on prostaglandins has been controversial, as some studies have found complete inhibition by systemic administration of COX inhibitors 86 and others only partial inhibition 71, 87 or none at all [88] [89] [90] . These discrepancies may be explained by differences in route of administration or species, as well as the time course of the effect. For example, in mice lacking either EP1 or EP3 receptors, the expected elevation of adrenocorticotropic hormone (ACTH) Figure 4 Neuronal pathways that may cause hyperalgesia in the first few hours of systemic inflammation in response to PGE 2 . PGE 2 made by vascular and perivascular cells along venules in the preoptic area acts on EP3 receptors, which are found in the MnPO. This results in disinhibition of descending inhibitory projections from the medial preoptic area (MPO) to the brainstem antinociceptive system, including neurons in the periaqueductal gray matter (PAG) that promote analgesia by activating descending serotoninergic (5-HT) neurons in the RMR, which in turn inhibit nociceptive neurons in the spinal dorsal horn. 92 . Such findings suggest a complex dynamic response, in which some components are prostaglandin dependent and some are not. Most of the work on neural circuitry has been done on this prostaglandin-dependent early component of the corticosteroid response, which will be the focus here (Fig. 5) . Sawchenko and colleagues avoided peritoneal irritation by examining the mechanisms for elevation of Crh mRNA in neurons in the PVH after acute administration of i.v. LPS or IL-1β in rats 93, 94 . They found increased cFos expression in catecholaminergic neurons in the ventrolateral medulla (VLM) and showed that the elevation of Crh mRNA is blocked by interrupting noradrenergic and adrenergic afferents from the VLM to the PVH. They then showed that there is increased expression of mRNAs encoding COX1 and COX2 in blood vessels in the VLM after IL-1β administration and that injection of PGE 2 into the VLM can increase Crh mRNA expression in the PVH. However, i.c.v. administration of a COX1 inhibitor only partially blocks the early ACTH and corticosterone responses to i.v. LPS or IL-1β, and a COX2 inhibitor has no effect 92 . These findings are consistent with the observations that a COX1 inhibitor prevents i.v. LPS from activating cFos expression in VLM catecholamine neurons that express EP3 receptors, which in turn activate PVH CRH neurons 92, 95 , but indicate that there are more steps, at least some of which do not depend on prostaglandins, to cause secretion of ACTH during an inflammatory response.
Matsuoka and colleagues examined the functions of different EP receptors in the corticosteroid response to LPS by measuring ACTH in blood 1 hour after injecting i.p. LPS in mice 91 . They found that the elevation of ACTH after LPS injection is absent in EP1 and EP3 knockout mice but unaffected in EP2 or EP4 knockout mice. LPS also increases cFos expression in the PVH, especially in CRH neurons. Surprisingly, the increased cFos in the PVH still occurs in EP1 and EP3 knockout mice, although it is prevented by administering an EP1 antagonist to EP3 knockout mice, suggesting that either EP1 or EP3 receptors can activate pathways that cause cFos expression in PVH neurons, but neither one alone is sufficient to increase CRH secretion. EP1 receptors, but not EP3 receptors, were found in the central nucleus of the amygdala, a source of afferents to the PVH.
Another potential site of action for PGE 2 would be the MnPO, which contains both EP1 and EP3 receptors and which projects to the PVH 83 . Both amygdala and MnPO neurons that project to the PVH also receive extensive noradrenergic inputs from the medulla. However, whether the cells projecting to the PVH from these sites bear EP receptors and what neurotransmitters they use are not known.
In summary, the cascade of mediators that are released during inflammation can act at several levels of the nervous system. Though peripheral nerves trigger some responses, there is strong evidence that the penetration of the inflammatory signal into the CNS requires the mediation of prostaglandins, especially for fever and feeding responses, and that prostaglandin-activated circuitry regulates sleep, hyperalgesia and corticosteroid responses as well. This linkage provides an opportunity to probe the CNS circuitry that the different prostaglandin receptors engage. Studies in the past decade have identified many of these circuits, and they suggest testable hypotheses about others. In addition, drugs that can differentially alter these responses may be of value in alleviating suffering due to the sickness syndrome without diminishing its adaptive effects. Figure 5 Neuronal pathways that may cause elevated secretion of corticosteroids in response to systemic inflammation. PGE 2 may act at several locations to facilitate release of CRH from PVH neurons, which in turn causes secretion of pituitary ACTH and hence of adrenal corticosteroids. First, PGE 2 activates medullary noradrenergic (NE) neurons in the A1 and A2 cell groups, which express EP1, EP3 and EP4 receptors (EP1R, EP3R, EP4R), an input that is required for increased cFos and CRH expression in PVH neurons. EP4 receptors are also expressed by PVH neurons, but apparently these are not necessary for corticosteroid secretion in response to LPS, which is normal in EP4 knockout mice. By contrast, genetic deletion of either EP1 or EP3 receptors prevents corticosteroid secretion in response to LPS. These receptors are also found on neurons in the MnPO, and EP1 receptors are found on neurons in the central nucleus of the amygdala (Amyg), both of which provide inputs to the CRHproducing cells in the PVH. 
